QIAGEN and EQT Private Equity announce agreement on a recommended voluntary all-cash public takeover offer

^

EQS-News: Crown NL Bidco B.V. / Schlagwort(e): Fusionen & Übernahmen

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary

all-cash public takeover offer

21.10.2026 / 23:38 CET/CEST

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

QIAGEN and EQT Private Equity announce agreement on a recommended voluntary

all-cash public takeover offer

* QIAGEN and EQT Private Equity agree on an all-cash public takeover offer

for all outstanding QIAGEN shares at an offer price of EUR46.50 per share,

a premium of 40.3% to the unaffected share price

* Following a comprehensive review of strategic options, QIAGEN's

Supervisory Board and Managing Board fully support the transaction and

agreed to unanimously recommend acceptance of the Takeover Offer

* QIAGEN to be better positioned to deliver on its full potential in a

private setting, while shareholders benefit from an attractive all-cash

premium and certain value

* Closing expected in mid-2027, subject to, inter alia, a minimum

acceptance threshold of 50% of the outstanding share capital plus one

QIAGEN share and customary regulatory clearances

Venlo and Amsterdam, the Netherlands, 21 October 2026 - QIAGEN N.V. (NYSE:

QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") and the EQT

XI fund ("EQT Private Equity") today announced an agreement under which

Crown NL Bidco B.V. (the "Bidder") announced its decision to make an

all-cash voluntary public takeover offer for the acquisition of all

outstanding QIAGEN shares at EUR46.50 per share (the "Takeover Offer").

The Bidder is a holding company indirectly controlled by EQT XI fund with

further indirect participations held by co-investors Luxinva S.A. (a

wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA)), and

CPP Investment Board Europe Inc. (a wholly-owned subsidiary of Canada

Pension Plan Investment Board (CPP Investments)). EQT Private Equity is

managed and controlled by affiliates of EQT AB with registered seat in

Stockholm, Sweden ("EQT").

The Takeover Offer follows a comprehensive review by QIAGEN's Supervisory

Board and Managing Board (together the "QIAGEN Boards") that assessed

QIAGEN's strategic prospects and included discussions with both strategic

and financial parties. The QIAGEN Boards believe the transaction will

provide the best environment for QIAGEN's next growth phase, giving QIAGEN

greater flexibility to invest for the long term under private ownership

while providing shareholders with attractive and certain cash value.

The Bidder will offer QIAGEN shareholders EUR46.50 in cash for each QIAGEN

share (the "Offer Price"), which represents an attractive premium of 40.3%

to the XETRA closing price of EUR33.15 per QIAGEN share on 8 July 2026, the

last trading day prior to the publication of market reports regarding

takeover interest from private equity firms, and 46.9% to the three-month

volume-weighted average price (VWAP) on XETRA of EUR31.66 per QIAGEN share up

to and including 8 July 2026.

The transaction values QIAGEN at approximately EUR10.8 billion in enterprise

value (approximately $12.1 billion at current exchange rates, including

approximately $1.1 billion of net debt).

Strategic review supports proposed transaction and partnership with EQT

Private Equity

The QIAGEN Boards unanimously concluded that the transaction is in the best

interest of QIAGEN and its business, taking into account the interests of

QIAGEN's stakeholders.

Stephen H. Rusckowski, Chairman of the Supervisory Board of QIAGEN, said:

"This transaction offers shareholders compelling value while positioning

QIAGEN for its next phase of development under private ownership. After

considering QIAGEN's stand-alone strategic prospects and the alternatives

available through discussions with strategic and financial parties, we

unanimously concluded that this is the best path forward for QIAGEN, its

shareholders and other stakeholders."

Jonathan M. Pratt, Chief Executive Officer of QIAGEN, said: "Since joining

QIAGEN, I have seen firsthand the quality of our people, technologies and

customer relationships. I also see clear opportunities to build on those

strengths and do more for customers. Under private ownership, we can move

faster and have greater freedom to put resources behind the most attractive

opportunities that align best with our long-term strategy. That can help us

grow the business in line with our priorities and create more opportunities

for our people to innovate, develop their careers and help shape the future

of QIAGEN."

Roland Sackers, Chief Financial Officer of QIAGEN, said: "This agreement

provides our shareholders with an attractive premium while giving QIAGEN a

strong partner that shares our strategic priorities and vision for the

future. With EQT's support and resources, we will strengthen our ability to

pursue new opportunities and expand our capabilities, building on the

excellent foundation our teams have created."

Matteo Thun-Hohenstein, Partner at EQT, said: "QIAGEN is an outstanding

global leader in the life science tools and diagnostics market. We have

closely followed the Company for many years and long admired the

long-standing reputation and positive impact of its products and services,

enabling customers to advance cutting-edge science, improve patient outcomes

and gain valuable insights from biological samples. QIAGEN's management team

and employees have built an exceptional company with a portfolio of highly

attractive products and respected brands, strong market positions and

considerable technical expertise. EQT brings deep sector experience, a

global network and operational capabilities, and we are proud to partner

with QIAGEN's highly talented and capable employees to further invest in

QIAGEN's continued product innovation and growth."

Michael Bauer, Global Co-Head of Healthcare at EQT, said: "This is a

landmark transaction for EQT and a powerful reflection of the deep sector

understanding, investment experience and network of expertise we have built

over the last three decades. QIAGEN sits at the heart of modern life

sciences and diagnostics, and we are thrilled to partner with it. We are

proud to be investing alongside ADIA and CPP Investments, whose long-term

perspective and experience with large-scale transactions make them

outstanding partners."

Long-term ownership to support QIAGEN's strategy

As part of the Business Combination Agreement (the "BCA"), EQT Private

Equity has agreed to support QIAGEN's long-term development, including

commitments relating to QIAGEN's strategy, business, key brands, operational

footprint, R&D activities, employee arrangements, prudent financing and

culture of excellence. Following completion of the transaction, QIAGEN will

continue to operate under the QIAGEN name and brand.

EQT is one of the world's leading active ownership investors, with EUR354

billion in assets under management and a three-decade track record of

developing and future-proofing companies. EQT brings deep healthcare and

life sciences experience, supported by around 100 investment professionals

across 15 countries, with over EUR30bn invested across more than 210 companies

in Healthcare globally. Its current and former portfolio companies include

SPT Labtech, Galderma, Parexel, Aldevron, Dako and HemoCue. These

investments underscore strong sector experience across life sciences that

are complementary to QIAGEN's business focus.

Transaction summary and approvals

The QIAGEN Boards unanimously approved the BCA and support the transaction.

The QIAGEN Boards have carefully considered the Takeover Offer and certain

corporate measures to be implemented after closing of the Takeover Offer

that will enable the Bidder to acquire full ownership of the entire business

of QIAGEN (the "Post-Closing Measures").

Under the terms of and subject to the conditions of the BCA, the QIAGEN

Boards will recommend that QIAGEN shareholders tender their shares into the

Takeover Offer and vote in favor of the resolutions relating to the

Post-Closing Measures and associated governance matters at an Extraordinary

General Meeting to be held during the initial acceptance period (the "EGM").

Their formal recommendation will be published in a position statement after

the Bidder publishes the offer document (the "Offer Document").

The Takeover Offer will be subject to a minimum acceptance threshold of 50%

of the Company's outstanding share capital plus one share, the adoption of

certain resolutions at the EGM, including approval of the Post-Closing

Measures, the adoption of a separate decision by the QIAGEN Boards to

implement the Post-Closing Measures (the "Implementation Decision"), merger

control and foreign investment clearances, and certain further conditions,

which will be set forth in the Offer Document.

The implementation of the Post-Closing Measures will result in the Bidder

acquiring full ownership of the entire business of the Company, and all

shareholders of QIAGEN who have not accepted the Takeover Offer receiving a

cash distribution in an amount per share equal to the Offer Price less

applicable withholding taxes, which may result in a lower net amount being

received than if such shareholders had accepted the Takeover Offer. In

connection with the implementation of the Post-Closing Measures, the

listings of QIAGEN shares on the FSE and the NYSE will be terminated.

Under the BCA, the QIAGEN Boards will take the Implementation Decision if

the Post-Closing Measures have been approved at the EGM by at least 80% of

the votes cast. Otherwise, the QIAGEN Boards may still take the

Implementation Decision if they determine, in accordance with their

fiduciary duties, that proceeding with the transaction, including the

Post-Closing Measures, is in the best interest of QIAGEN, taking into

account the interests of its shareholders and other stakeholders and subject

to the support of a substantial majority of its shareholder base.

In determining whether the transaction has the support of a substantial

majority of its shareholder base and whether the voting results provide a

balanced reflection of the underlying shareholder support, the QIAGEN Boards

may consider, amongst other things, the percentage of votes cast in favor of

the Post-Closing Measures, attendance at the EGM, as well as the number of

votes cast in favor of the Post-Closing Measures by longer-term shareholders

compared to those who acquired shares subsequent to the announcement with

the aim of frustrating the transaction or pursuing event-driven hedge fund

strategies.

Closing of the Takeover Offer is currently expected in mid-2027. If closing

has not occurred within 10 months of the date of this announcement because

required regulatory approvals remain pending, QIAGEN may elect under the BCA

to pay shareholders an interim dividend of up to $0.47 per share. Any such

interim dividend would not be deducted from the Offer Price.

Until closing of the Takeover Offer, QIAGEN will continue to operate as an

independent company under its current management.

Next steps

The Takeover Offer will be made pursuant to the terms and conditions set out

in the Offer Document to be approved by the German Federal Financial

Supervisory Authority ("Bafin"). The Offer Document will be published

following clearance by Bafin, at which point the acceptance period for the

Takeover Offer will commence. On the same date, the Bidder will commence the

Takeover Offer in the United States and file a tender offer statement on

Schedule TO with the U.S. Securities and Exchange Commission ("SEC"). The

Offer Document (in German and a non-binding English translation) and other

information pertaining to the Takeover Offer will be made available in

accordance with the German Securities Acquisition and Takeover Act

(Wertpapiererwerbs-

und Übernahmegesetz - WpÜG) on the Bidder's website at www.eqt-offer.com,

and the Schedule TO and related filings will be available through the SEC's

website at www.sec.gov.

Certainty of funds

EQT Private Equity has obtained committed equity and debt financing

sufficient to fund the offer consideration and related transaction costs.

The transaction is not subject to any financing condition. Morgan Stanley,

Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are acting as

bookrunnners and mandated lead arrangers for the committed debt financing.

Advisors

Moelis & Company LLC and Goldman Sachs Bank Europe SE are serving as

financial advisors to QIAGEN, and Perella Weinberg Partners is serving as

financial advisor to the Supervisory Board. De Brauw Blackstone Westbroek

N.V., Linklaters LLP and Davis Polk & Wardwell LLP are serving as legal

counsel to QIAGEN.

Morgan Stanley & Co. International plc ("Morgan Stanley") and Jefferies LLC

("Jefferies") are serving as lead financial advisors to EQT Private Equity,

and Deutsche Bank is serving as financial advisor. Milbank is serving as

lead legal advisor, with Stibbe and Paul Weiss serving as further legal

advisors. Clifford Chance is serving as legal advisor to ADIA and

Freshfields as legal advisor to CPP Investments.

Contacts

QIAGEN

Public Relations: pr@QIAGEN.com

Investor Relations: ir@QIAGEN.com

EQT

International media: EQT Press Office press@eqtpartners.com

DACH media: Isabel Henninger, Kekst CNC, isabel.henninger@kekstcnc.com, +49

174 9409955

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in

Sample to Insight solutions that enable customers to extract and analyze

molecular information from biological samples containing the building blocks

of life. Our Sample technologies isolate and process DNA, RNA and proteins

from blood, tissue and other materials. Assay technologies prepare these

biomolecules for analysis, while bioinformatics support the interpretation

of complex data to deliver actionable insights. Automation solutions

integrate these steps into streamlined, cost-effective workflows. QIAGEN

serves more than 500,000 customers worldwide in the Life Sciences (academia,

pharmaceutical R&D and industrial applications such as forensics) and

Molecular Diagnostics (clinical healthcare). As of September 30, 2026,

QIAGEN employed about 5,400 people across more than 35 locations. For more

information, visit www.qiagen.com.

About EQT

EQT is a purpose-driven global investment organization focused on active

ownership strategies. With a Nordic heritage and a global mindset, EQT has a

track record of more than three decades of developing companies across

multiple geographies, sectors and strategies. EQT has investment strategies

covering all phases of a business' development, from start-up to maturity.

EQT has EUR354 billion in total assets under management (EUR195 billion in

fee-generating assets under management) as of 30 September 2026, within four

business segments - Private Capital, Infrastructure, Real Estate and

Secondaries.

With its roots in the Wallenberg family's entrepreneurial mindset and

philosophy of long-term ownership, EQT is guided by a set of strong values

and a distinct corporate culture. EQT manages and advises funds and vehicles

that invest across the world with the mission to future-proof companies,

generate attractive returns and make a positive impact with everything EQT

does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect

subsidiaries, which include general partners and fund managers of EQT funds

as well as entities advising EQT funds. EQT has offices in more than 25

countries across Europe, Asia Pacific, the Americas and the Middle East and

has more than 2,000 employees.

More info: www.eqtgroup.com

Follow EQT on LinkedIn, X, YouTube and Instagram

About ADIA

Established in 1976, the Abu Dhabi Investment Authority ("ADIA") is a

globally-diversified investment institution that prudently invests funds on

behalf of the Government of Abu Dhabi through a strategy focused on

long-term value creation.

For more information:

https://www.adia.ae

For further details, please contact:

Garry Nickson Abu Dhabi Investment Authority

T: +971 2 415 6085 E: Garry.Nickson@adia.ae

About CPP Investments

Canada Pension Plan Investment Board (CPP Investments(TM)) is a professional

investment management organization that manages the Canada Pension Plan Fund

in the best interests of the more than 22 million contributors and

beneficiaries. In order to build diversified portfolios of assets, we make

investments around the world in public equities, private equities, real

estate, infrastructure and fixed income. Headquartered in Toronto, with

offices in Hong Kong, London, Mumbai, New York City, São Paulo and Sydney,

CPP Investments is governed and managed independently of the Canada Pension

Plan and at arm's length from governments. At June 30, 2026, the Fund

totaled C$863.6 billion. For more information, please visit

www.cppinvestments.com or follow us on LinkedIn, Instagram or on X

@CPPInvestments.

For further details, please contact:

Frank Switzer

T: + 1-416-523-8039 E: media@cppib.com

Forward-looking statements

Certain statements contained in this communication may be considered

forward-looking statements within the meaning of Section 27A of the U.S.

Securities Act of 1933, as amended ("Securities Act"), and Section 21E of

the U.S. Securities Exchange Act of 1934, as amended. These statements can

be identified by the use of forward-looking terminology such as "believe",

"hope", "plan", "intend", "seek", "may", "will", "could", "should", "would",

"expect", "anticipate", "estimate", "continue", "target" or other similar

words. To the extent that any of the statements contained herein relating to

QIAGEN N.V.'s ("QIAGEN") products, timing for launch and development,

marketing and/or regulatory approvals, financial and operational outlook,

growth and expansion, acquisitions, collaborations, markets, strategy or

operating results, including without limitation its expected net sales, net

sales of particular products, net sales in particular geographies, adjusted

net sales, expansion of adjusted operating income margin, returns to

shareholders, progressive dividend payments, product portfolio management,

product launches (including anticipated launches of QIAGEN's sequencing

solutions, testing platforms, panels and systems), leveraging AI technology,

improvements in operating and financial leverage, currency movements against

the U.S. dollar, plans for investment in QIAGEN's portfolio and share

repurchase commitments, QIAGEN's expectations relating to QIAGEN's adjusted

tax rate, debt maturity and repayment, QIAGEN's ability to grow adjusted

earnings per share at a greater rate than sales, QIAGEN's ability to improve

operating efficiencies and maintain disciplined capital allocation, are

forward-looking, such statements are based on current expectations and

assumptions that involve a number of uncertainties and risks. These include,

but are not limited to, risks associated with QIAGEN's dependence on the

development and success of new products; management of growth and expansion

of operations (including the effects of currency fluctuations, tariffs, tax

laws, regulatory processes and supply chain dependencies); variability of

operating results; integration of acquired businesses; changes in

relationships with customers, suppliers and strategic partners; competition;

rapid or unexpected changes in technologies; fluctuations in demand for

QIAGEN's products (including fluctuations due to general economic

conditions, the level and timing of customers' funding, budgets and other

factors, including delays or limits in the amount of reimbursement approvals

or public health funding); QIAGEN's ability to obtain and maintain product

regulatory approvals; difficulties in successfully adapting QIAGEN's

products to integrated solutions and producing such products; the ability of

QIAGEN to identify and develop new products and to differentiate and protect

QIAGEN's products from competitors' products; market acceptance of new

products and the integration of acquired technologies and businesses;

actions of governments, global or regional economic developments, including

inflation and changing interest rates, weather or transportation delays,

natural disasters, cyber security breaches, political or public health

crises and the resulting impact on the demand for QIAGEN's products and

other aspects of QIAGEN's business, or other force majeure events;

litigation risk, including patent litigation and product liability; debt

service obligations; volatility in the public trading price of QIAGEN

shares; as well as the possibility that expected benefits related to recent

or pending acquisitions may not materialize as expected; and the other

factors discussed under the heading "Risk Factors" in QIAGEN's most recent

Annual Report on Form 20-F. For further information, please refer to

QIAGEN's filings with the U.S. Securities and Exchange Commission (the

"SEC").

The forward-looking statements in this communication also include statements

relating to the tender offer. Additional important factors that could cause

actual results to differ materially from those indicated by such

forward-looking statements include risks and uncertainties relating to: the

proposed transaction not being timely completed, if completed at all;

uncertainties as to the number of QIAGEN ordinary shares that will be

tendered in the tender offer; the possibility that competing offers will be

made; the possibility that the conditions to the tender offer may not be

satisfied or waived; the occurrence of any event, change or other

circumstance that could give rise to the termination of the business

combination agreement; the completion of the post-closing measures and

implementation of the financing arrangements contemplated in connection with

the tender offer; the receipt of, and any conditions associated with, any

exemptive or other relief requested from the SEC in connection with the

tender offer; regulatory approvals required for the transaction not being

timely obtained, if obtained at all, or being obtained subject to

conditions; prior to the completion of the transaction, QIAGEN's business

experiencing disruptions due to transaction-related uncertainty or other

factors making it more difficult to maintain relationships with employees,

customers, licensees, other business partners or governmental entities;

difficulty retaining key employees; and the outcome of any legal proceedings

related to the proposed transaction. The forward-looking statements

contained in this communication speak only as of the date of this

communication. Neither the Bidder, EQT Private Equity nor QIAGEN undertakes

any obligation to publicly update any forward-looking statement, whether as

a result of new information, future events or otherwise, except to the

extent required by applicable law.

Additional Information and Where to Find it

The tender offer referenced herein has not yet commenced. This communication

is for informational purposes only and is neither an offer to purchase nor a

solicitation of an offer to sell any ordinary shares of QIAGEN or any other

securities, nor is it a substitute for the tender offer materials that the

Bidder will file with the SEC and publish in Germany. The terms and

conditions of the tender offer will be published in, and the offer to

purchase ordinary shares of QIAGEN will be made only pursuant to, the Offer

Document and related offer materials prepared by the Bidder and as approved

by the German Federal Financial Supervisory Authority (Bundesanstalt für

Finanzdienstleistungsaufsicht, "BaFin"). Once the necessary permission from

BaFin has been obtained, the Offer Document and related offer materials will

be published in Germany and also filed with the SEC in a tender offer

statement on Schedule TO at the time the tender offer is commenced. QIAGEN

intends to file a solicitation / recommendation statement on Schedule 14D-9

with the SEC with respect to the tender offer; in addition, QIAGEN will

publish a document combining the recommendation statement pursuant to

Section 27 of the German Securities Acquisition and Takeover Act

(Wertpapiererwerbs-

und Übernahmegesetz - "WpÜG") and the position statement pursuant to Section

18 and Annex G of the Dutch Decree on public offers (Besluit openbare

biedingen Wft). The Offer Document for the tender offer (in German and in

English) containing the detailed terms and conditions of, and other

information relating to, the tender offer will, among other things, be

published on the internet at www.eqt-offer.com.

Acceptance of the tender offer by shareholders that are resident outside

Germany and outside of the United States may be subject to further legal

requirements and/or restrictions. With respect to the acceptance of the

tender offer outside Germany and outside of the United States, no

responsibility is assumed for the compliance with such legal requirements

applicable in the respective jurisdiction.x

THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER

OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE

SOLICITATION / RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE

AMENDED FROM TIME TO TIME, AS WELL AS QIAGEN'S RECOMMENDATION STATEMENT

PURSUANT TO SECTION 27 WPÜG AND POSITION STATEMENT PURSUANT TO SECTION 18

AND ANNEX G OF THE DUTCH DECREE ON PUBLIC OFFERS (Besluit openbare biedingen

Wft) WILL CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF

QIAGEN ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME

AVAILABLE BECAUSE THEY, AND NOT THIS DOCUMENT, WILL GOVERN THE TERMS AND

CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY WILL CONTAIN IMPORTANT

INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION

REGARDING TENDERING THEIR ORDINARY SHARES.

The tender offer materials, including the offer to purchase and the related

letter of transmittal and certain other tender offer documents, and the

solicitation/recommendation statement on Schedule 14D-9 (when they become

available) and other documents filed with the SEC by the Bidder or QIAGEN,

may be obtained free of charge at the SEC's website at www.sec.gov or at the

Bidder's website at www.eqt-offer.com. In addition, the Bidder's tender

offer statement and other documents it will file with the SEC will be

available at www.eqt-offer.com. Furthermore, copies of the Offer Document

will also be available free of charge by contacting the information agent to

be identified in the Offer Document.

Governing Law

The tender offer will be made and implemented under the laws of the Federal

Republic of Germany, in particular the WpÜG, certain applicable provisions

of the laws of the Netherlands and certain applicable provisions of the

securities laws of the United States of America. Any agreement that is

entered into as a result of accepting the tender offer will be exclusively

governed by the laws of the Federal Republic of Germany and is to be

interpreted in accordance with such laws.

Acquisition of Shares Outside the Tender Offer

Each of EQT Private Equity and the Bidder reserves the right, within the

limits of applicable law and subject to any exemptive relief from the SEC,

to directly or indirectly acquire shares in QIAGEN outside of the tender

offer, whether on or off the stock exchange. Any such purchases or

arrangements will be made outside the United States and in compliance with

applicable law and subject to any exemptive relief from the SEC. To the

extent such acquisitions occur, information about them, including the number

of, and the price for, the acquired shares in QIAGEN will be published

without undue delay, if and to the extent required under the applicable

statutory provisions.

Information in respect of EQT XI

Any information in respect of the EQT XI fund ("EQT XI") contained herein

does not constitute an offer to sell, nor a solicitation of an offer to buy,

any security, and may not be used or relied upon in connection with any

offer or solicitation of EQT XI. Any offer or solicitation in respect of EQT

XI will be made only through a confidential private placement memorandum and

related documents which will be furnished to qualified investors on a

confidential basis in accordance with applicable laws and regulations. Any

securities of EQT XI referred to herein have not been and will not be

registered under the Securities Act and may not be offered or sold without

registration thereunder or pursuant to an available exemption therefrom. Any

offering of securities of EQT XI to be made in the United States would have

to be made by means of an offering document that would be obtainable from

the issuer or its agents and would contain detailed information about the

issuer of the securities and its management, as well as financial

information. Any EQT XI securities may not be offered or sold in the United

States absent registration or an exemption from registration.

---------------------------------------------------------------------------

21.10.2026 CET/CEST Veröffentlichung einer Corporate News/Finanznachricht,

übermittelt durch EQS News - ein Service der EQS Group.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die EQS Distributionsservices umfassen gesetzliche Meldepflichten, Corporate

News/Finanznachrichten und Pressemitteilungen.

Originalinhalt anzeigen:

https://eqs-news.com/?origin_id=9567e4cd-cd95-11f1-9d22-0a083a71a9ab&lang=de

---------------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: Crown NL Bidco B.V.

Johannes Vermeerplein 9

1071 Amsterdam

Niederlande

EQS News ID: 2419988

Ende der Mitteilung EQS News-Service

---------------------------------------------------------------------------

2419988 21.10.2026 CET/CEST

°